Snapshot from Aug 23, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / VivoSim regains Nasdaq compliance
Regulatory compliance update

VivoSim regains Nasdaq compliance

Analysis based on 6 articles · First reported Aug 06, 2026 · Last updated Aug 06, 2026

Sentiment
40
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The news of regained Nasdaq compliance and improved cash position is positive for VivoSim's stock, reducing delisting risk and providing liquidity. The milestone payment from Eli Lilly and financing strengthen the company's balance sheet, supporting its growth plans.

Biotechnology Pharmaceutical
Event Summary

VivoSim Labs, Inc. (Nasdaq: VIVS) announced on August 6, 2026 that it regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders' equity of $2.5 million. The company received a $5.0 million milestone payment from Eli Lilly and Company and $1.0 million released from escrow, both related to the prior sale of its FXR program. Additionally, VivoSim completed a financing on July 17, 2026, raising gross proceeds of $4.0 million. As of August 3, 2026, cash on hand was approximately $10.1 million. The company reiterated guidance of 500%+ revenue growth in Fiscal Year 2027.

Key Actions
90 VivoSim Labs regained compliance Nasdaq
80 Eli Lilly and Company paid milestone VivoSim Labs
60 VivoSim Labs agreed to amend warrants
Entities Involved
priv
VivoSim Labs
VivoSim regained Nasdaq compliance, received milestone payments, and completed financing, boosting its cash position and reducing delisting risk.
Importance 100.0 Sentiment 70.0
stock
Eli Lilly and Company
Eli Lilly made a $5.0 million milestone payment to VivoSim related to the FXR program sale, a routine contractual obligation.
Importance 60.0 Sentiment 10.0
exch
Nasdaq
Nasdaq confirmed VivoSim's compliance with listing rule 5550(b)(1), allowing continued listing.
Importance 40.0 Sentiment 0.0
govactor
United States — United States Securities and Exchange Commission
The SEC is the regulator receiving VivoSim's filings; the company provided supplemental information to investors.
Importance 20.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
The FDA's roadmap favoring non-animal testing methods is mentioned as a potential growth driver for VivoSim's business.
Importance 10.0 Sentiment 0.0
Relationships
Eli Lilly and Company related ↔ Nasdaq
Eli Lilly and Company related ↔ United States — Food and Drug Administration
Nasdaq regulated ↔ United States — United States Securities and Exchange Commission Nasdaq operates as a registered national securities exchange under the direct oversight and regulatory authority of the
Nasdaq related ↔ United States — Food and Drug Administration
United States — United States Securities and Exchange Commission related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.